EUVIMEDEUVIMED entdecken
Open Access

Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C

Eiichi Ogawa, Nicholas Chien, Leslie Kam, Yee Hui Yeo, Fanpu Ji, Daniel Q Huang, Ramsey Cheung, Mindie H Nguyen

JAMA Internal Medicine · 01.02.2023 · 183 (2) · 97

DOI: 10.1001/jamainternmed.2022.5699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.02.2023. Verfasst von Eiichi Ogawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis C, Chronic, Liver Neoplasms, Hepatitis C. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Chronic hepatitis C (CHC) and its complications are associated with high rates of morbidity and mortality. However, large-scale data analysis of the long-term liver and nonliver effects of direct-acting antiviral (DAA) treatment has been limited.

Objective

To assess the association of hepatitis C virus elimination through DAA treatment with the risk of liver and nonliver morbidity and mortality during long-term follow-up among a large nationwide cohort of insured patients with CHC in the US. Design, Setting, and Participants This was a retrospective cohort study of 245 596 adult patients with CHC using data from the Optum Clinformatics Data Mart database, 2010 to 2021. Of the total cohort, 40 654 patients had received 1 or more prescriptions for DAA medication (without interferon), and 204 942 patients were untreated. Exposure Treatment with a DAA. Main Outcomes and Measures Incidence of hepatocellular carcinoma (HCC), liver decompensation, relevant nonliver events (nonliver cancer, diabetes, chronic kidney disease, cardiovascular disease), and overall mortality.

Results

The DAA-treated cohort (vs untreated) were older (mean [SD] age, 59.9 [10.8] vs 58.5 [13.0] years; P < .001); more likely to be male (25 060 [62%] vs 119 727 [58%] men; P < .001) and White (23 937 [59%] vs 115 973 [57%]; P < .001) individuals; and more likely to have diabetes (10 680 [26%] vs 52 091 [25%]; P < .001) or cirrhosis (17 971 [44%] vs 60 094 [29%]; P < .001). Comparing DAA-treated with untreated patients, the incidence (per 1000 person-years) of liver outcomes (eg, decompensation, 28.2 [95% CI, 27.0-29.4] vs 40.8 [95% CI, 40.1-41.5]; P < .001, and HCC in compensated cirrhosis, 20.1 [95% CI, 18.4-21.9] vs 41.8 [95% CI, 40.3-43.3]; P < .001) and nonliver outcomes (eg, diabetes, 30.2 [95% CI, 35.4-37.7] vs 37.2 [95% CI, 36.6-37.9]; P < .001; and chronic kidney disease, 31.1 [95% CI, 29.9-32.2] vs 34.1 [95% CI, 33.5-34.7]; P < .001) were significantly lower in treated patients. The all-cause mortality rates per 1000 person-years were also significantly lower in DAA-treated compared with untreated patients (mortality, 36.5 [95% CI, 35.4-37.7] vs 64.7 [95% CI, 63.9-65.4]; P < .001). In multivariable regression analysis, DAA treatment was independently associated with a significant decrease in the risk of liver (adjusted hazard ratio [aHR] for HCC, 0.73; decompensation, 0.36), nonliver (aHR for diabetes, 0.74; chronic kidney disease, 0.81; cardiovascular disease, 0.90; nonliver cancer, 0.89), and mortality outcomes (aHR, 0.43). Conclusions and Relevance The findings of this retrospective cohort study indicate that DAA treatment for insured patients with CHC was associated with improved liver- and nonliver outcomes, and ultimately, with long-term overall survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHepatitis C, ChronicLiver NeoplasmsHepatitis CAdultHumansMaleMiddle AgedFemaleAntiviral AgentsRetrospective StudiesLiver Cirrhosis

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California.
  • Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California.
  • Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Ogawa, E., Chien, N., Kam, L., Yeo, Y. H., Ji, F., Huang, D. Q., Cheung, R., & Nguyen, M. H. (2023). Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C. JAMA Internal Medicine, 183(2), 97. https://doi.org/10.1001/jamainternmed.2022.5699

Vancouver

Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, et al. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C. JAMA Internal Medicine. 2023;183(2):97. doi:10.1001/jamainternmed.2022.5699

BibTeX
@article{Ogawa2023,
  author = {Ogawa, Eiichi and Chien, Nicholas and Kam, Leslie and Yeo, Yee Hui and Ji, Fanpu and Huang, Daniel Q and Cheung, Ramsey and Nguyen, Mindie H},
  title = {Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C},
  journal = {JAMA Internal Medicine},
  year = {2023},
  volume = {183},
  number = {2},
  pages = {97},
  doi = {10.1001/jamainternmed.2022.5699}
}
Kostenlos starten →